AstraZeneca’s COVID-19 vaccine may receive EUA from India soon

By Nikita Chaurasia  Date: 2020-12-24

AstraZeneca’s COVID-19 vaccine may receive EUA from India soon

Reportedly, India intends to grant emergency use authorization (EUA) to Oxford/AstraZeneca’s coronavirus vaccine by next week, following submission of some additional data to the concerned authorities by a few local manufacturers. India could be the first country to approve AstraZeneca’s vaccine as the British drugmaker continues the process of examining data from its clinical trials.

Being the biggest vaccine-making country worldwide, India intends to begin immunizing the population starting next month and is in talks of approving EUA applications for Coronavirus vaccines made by local company Bharat Biotech as well as the American pharmaceutical giant Pfizer Inc., claimed trusted sources.

In this context, experts cite that the AstraZeneca-Oxford COVID-19 shot is essential in countries with lower-income and hot climatic conditions as it is inexpensive, easy to transport, and can be stored at normal fridge temperatures for long periods.

The Central Drugs Standard Control Organization (CDSCO) of India had initially assessed the three applications on 9th December and requested more information from all the pharmaceutical firms, including Serum Institute of India (SII), the company which is reportedly producing the AstraZeneca vaccines.

Although Serum Institute has provided all the data required, the authorities are reportedly awaiting information from Pfizer, and some additional information from Bharat Biotech, sources confirmed.

According to the data released by AstraZeneca of their late-stage trials in Brazil and in the U.K., the vaccine showed 62% efficacy among trial participants who were given two dosages each, and 90% efficacy for a smaller group of people given first a half, and then a full dosage, which evidently forms the base of the anticipated approval.

If sources are to be believed, only two full-dose regimens of the COVID-19 vaccine are being considered by the Indian regulator despite its lower success rate.

India is yet to sign a vaccine supply agreement with any pharmaceutical company; however, Serum Institute has reportedly stockpiled over 50 million doses of the AstraZeneca vaccines and intends to make a total of 400 million doses by July 2021, cited sources knowledgeable with the matter.

Source Credits –

https://in.reuters.com/article/uk-health-coronavirus-india-vaccine-excl/exclusive-india-likely-to-approve-astrazeneca-vaccine-by-next-week-sources-idINKBN28W27I

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...